PolyPid CEO granted 149,000 stock options
PolyPid Ltd. granted 149,000 stock options to Chief Executive Officer Akselbrad Dikla Czaczkes.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
PolyPid Ltd. granted 149,000 stock options to Chief Executive Officer Akselbrad Dikla Czaczkes. The options relate to Ordinary Shares at an exercise price of $4.46 per share, vest quarterly from May 11, 2026 through May 11, 2030, and expire on July 15, 2036.
Insider Trade Summary
Grant/Award: 149,000 shares
Grant/Award
1 txn
Insider
Akselbrad Dikla Czaczkes
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) F1 | 149,000 | $4.46 | $665K |
Holdings After Transaction:
Stock option (right to buy) — 149,000 contracts (Direct)
Holdings Before and After:
Stock option (right to buy), 0 to 149,000 contracts (Direct)
Footnotes (1)
- F1. The options vest on a quarterly basis beginning May 11, 2026 until May 11, 2030.
Key Figures
Options granted: 149,000
Exercise price: $4.46 per share
Underlying Ordinary Shares: 149,000
+4 more
7 metrics
Options granted
149,000
Stock options granted to CEO Akselbrad Dikla Czaczkes
Exercise price
$4.46 per share
Exercise price of the stock option grant dated 2026-07-15
Underlying Ordinary Shares
149,000
Ordinary Shares underlying the granted stock options
Expiration date
2036-07-15
End of term for the granted stock options
Vesting start date
2026-05-11
Quarterly vesting begins for the option grant
Vesting end date
2030-05-11
Quarterly vesting concludes for the option grant
Options held after transaction
149,000
Total derivative securities following the reported grant
Key Terms
Stock option (right to buy), exercise price, expiration date, vesting
4 terms
Stock option (right to buy) financial
"security_title": "Stock option (right to buy)""
exercise price financial
"conversion_or_exercise_price": "4.4600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date": "2036-07-15""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"The options vest on a quarterly basis beginning May 11, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stock option grant did PolyPid (PYPD) report for its CEO?
PolyPid (PYPD) reported a grant of 149,000 stock options to Chief Executive Officer Akselbrad Dikla Czaczkes. Each option relates to an Ordinary Share and was granted with specific vesting and expiration terms defined in the Form 4 disclosure.
What is the exercise price and term of the PolyPid (PYPD) CEO stock options?
The CEO’s stock options have an exercise price of $4.46 per share and an expiration date of 2036-07-15
How do the PolyPid (PYPD) CEO stock options vest?
The options vest on a quarterly basis, beginning May 11, 2026 and continuing until May 11, 2030. This schedule gradually makes portions of the 149,000-option grant exercisable over four years, rather than all at once on the grant date.
What security type is involved in PolyPid (PYPD) CEO’s reported transaction?
The transaction involves a “Stock option (right to buy)” derivative security tied to PolyPid’s Ordinary Shares. Each option represents the right to purchase one Ordinary Share at the fixed exercise price, subject to the vesting and expiration terms disclosed.
How many options does the PolyPid (PYPD) CEO hold after this grant?
Following the reported grant, the CEO is shown holding 149,000 stock options related to Ordinary Shares. These options correspond to 149,000 underlying shares and will become exercisable over time in line with the stated quarterly vesting schedule.
AI-generated analysis. How Rhea-AI works. Not financial advice.
